A Novel Gene Therapy Vector

Propriety Gene Vectors

Based on a triple mutant AAV6.2FF capsid
- Lower immunogenicity
- Improved transgene expression
Cellexa [adeno-associated virus (AAV6) human ensereptide-Fc fusion protein gene therapy]
The ensereptide in Cellexa is the human lactoferrin derived peptide linked to human Fc protein. This is Cellastra's Anti-Scaring Fusion protein.
The ensereptide (PXL01) has been shown to have higher anti-inflammatory, anti-scarring and anti-bacterial properties, than its full molecule i.e., lactoferrin
Scarlexa and Fibrexa are different formulations of Cellexa, where Scarlexa is a dermal formulation and Fibrexa is inhaled formulation.

Mechanism of Action

Expression of Gene Vector in Mice

Gene vector PXL01 expression in mice of PXL01 for 77 Days

Product Candidates

Fibrexa for mitigation of respiratory infections

FIBREXA is a formulation for inhalation by high risk patients e.g. elderly or other patients with risk factors for developing long-term complications with fibrosis after respiratory infections (eg. Influenza, RSV and COVID-19).

Figure showing normal lung vs. idiopathic (unknown cause) pulmonary fibrosis.

Scarlexa to prevent dermal scarring after burn injuries

Gene therapy for dermal application to prevent scarring after burn injury. Applied topically by spray or ointment suitable for larger body surface area.

Scarlexa to prevent scarring or adhesions after surgery

For prevention of scarring or adhesions after surgery, Scarlexa is applied before wound closure or injected subcutaneously into the wound area. Shown below is adhesions of the lung (a). Surgery is often used to remove adhesions (b). Treatment with Scarlexa prevents the return of adhesions.

Before and after removal of adhesion in body cavity

How Does It Work?

Administration of the viral gene vector:

May Enable continuous production of anti-scarring peptides in the cells of the wound area for many weeks or months.
May Help mitigate hyper-immune response (cytokine storm), excessive fibrin formation, secondary infections and excessive scar/fibrosis formation.